Tumor antigens identified in CRC tissues were then validated and quantified with synthetic peptides to determine to what extent they were overexpressed on tumor compared with matched NAT, and we also investigated their predicted immunogenicity and intertumoral distribution to evaluate their clinical potential (Fig. 1, pink box). Here, BRD2 is linked to neoplasm.